1
|
Üstün F, Ustabaşıoğlu F, Tokuç B, Bülbül BY, Çelik M, Aytürk S. PAGET'S DISEASE OF THE BONE FOUND INCIDENTALLY ON F-18 FDG PET/CT: CLINICAL SIGNIFICANCE AND DIFFERENTIAL DIAGNOSTIC CRITERIA. Acta Endocrinol (Buchar) 2023; 19:292-300. [PMID: 38356987 PMCID: PMC10863963 DOI: 10.4183/aeb.2023.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Abstract
Background Paget Disease (PD) is usually asymptomatic and discovered incidentally, it is known that it is exhibited low to high grade increased F-18 FDG uptake. Aim In this study, we investigated the distinguishability of FDG PET/CT in incidental PD cases from other bone diseases and at different stages of the disease. Patients and Methods In this cross-sectional, descriptive study, "Paget" identification associated with PET/CT reports was found in 69 of 18,119 studies (~3.8%). Of the 45 patients (33 males and 12 females) eligible for inclusion in the study, 35.6% had monostotic and 64.4% had polyostotic disease (p>0.5). There was no statistically significant difference in biochemical parameters between groups. Results According to the radiological appearance of the patients, 36 were in the mixed stage and 9 were in the blastic stage. Only the difference in ALP and creatinine values between the groups was statistically significant. SUVmax, SUVmean and HU values were found to be statistically significantly higher in pagetoid bones compared to control bone lesions. For SUVmax for PD bone lesion we found the 2.55 cutoff point with a sensitivity of 91% and a specificity of 84%. Conclusion The specific radiological appearance of bone lesions and the evaluation of metabolic activity compared to normal bone seem to help differentiate PD from other lesions. Prospective studies are needed in the differentiation of FDG's disease stage and treatment response evaluation. The ability to differentiate between benign and malignant FDG avid bone lesions in oncological patients' enables appropriate patient management, including avoiding unnecessary additional invasive procedures such as bone biopsy.
Collapse
Affiliation(s)
- F. Üstün
- Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne
| | - F.E. Ustabaşıoğlu
- Trakya University, Faculty of Medicine, Department of Radiology, Edirne
| | - B. Tokuç
- Namık Kemal University, Faculty of Medicine, Department of Public Health, Tekirdağ
| | - B. Yımaz Bülbül
- Namık Kemal University, Faculty of Medicine, Department of Public Health, Tekirdağ
| | - M. Çelik
- Trakya University, Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Edirne
| | - S. Aytürk
- Kayseri City Hospital, Department of Endocrinology and Metabolic Diseases, Kayseri, Turkey
| |
Collapse
|
2
|
Gogas Yavuz D, Aytürk S, Çetinkalp Ş, Bayraktar F, Kulaksızoğlu M, Hekimsoy Z, Aydın H, Uygur M, Deniz F, İpekçi S, Atmaca A, Saraç F, Özdemir N, Cantürk Z, Mert M, Sancak S, Ertörer E, Duran C, Akarsu E, Deyneli O, Selek A, Gürlek A. Clinical and demographic aspects of Paget disease of bone: A multicentric study from Turkey. Eur J Rheumatol 2021; 8:156-161. [PMID: 33284101 PMCID: PMC9770406 DOI: 10.5152/eurjrheum.2020.20139] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE Paget disease of bone (PDB) is a metabolic bone disease that has been rarely reported in the Eastern countries. This study aimed to evaluate the clinical and demographic characteristics of patients with PDB followed up at endocrinology clinics in Turkey. METHODS An invitation was sent to tertiary endocrinology clinics to complete a survey on the demographic, clinical, radiological, and laboratory parameters, as well as treatment modalities of patients with PDB. This study enrolled clinically and radiologically proven 185 patients with PDB from 18 endocrinology centers based in 10 cities of Turkey. RESULTS This cohort of PDB had female preponderance (women/men: 105/80) with a mean age, during diagnosis, of 57±10 years. Most of the patients (59.6%) were symptomatic at diagnosis. Bone pain and headache were the predominant clinical symptoms. Polyostotic disease was observed in 67.5% (n=125) of patients. Frequently affected bones were skull (41.6%), pelvis (53.5%), spine (41%), and femur (25.4%). Moreover, 17 patients with skull involvement had hearing loss. Mean serum alkaline phosphatase (ALP) level (552±652 IU/L; range: 280-5762 IU/L) was over the normal reference cutoff with normal serum calcium levels. Intravenous bisphosphonates (zoledronic acid, 5 mg; pamidronate, 60-90 mg) were the most used drugs (75%) for the treatment of PDB. Most of the patients (87.1%) treated with intravenous bisphosphonates responded well, with a decrease in serum ALP level (117±114 IU/L) in the 12th month of therapy. Furthermore, 16 patients relapsed after the second year of therapy; 3 patients did not respond to the initial intravenous bisphosphonate treatment. CONCLUSION The patients with PDB followed up by endocrinology clinics of Turkey exhibited polyostotic disease with classical clinical, radiological, and biochemical features and women's predominance with good response to intravenous bisphosphonate therapy.
Collapse
Affiliation(s)
- Dilek Gogas Yavuz
- Department of Endocrinology and Metabolism, Marmara University School of Medicine, İstanbul,
Turkey
| | - Semra Aytürk
- Department of Endocrinology and Metabolism, Trakya University School of Medicine, Edirne,
Turkey
| | - Şevki Çetinkalp
- Department of Endocrinology and Metabolism, Ege University School of Medicine, İzmir,
Turkey
| | - Fırat Bayraktar
- Department of Endocrinology and Metabolism, Dokuz Eylül University School of Medicine, İzmir,
Turkey
| | - Mustafa Kulaksızoğlu
- Department of Endocrinology and Metabolism, Necmettin Erbakan University School of Medicine, Konya,
Turkey
| | - Zeliha Hekimsoy
- Department of Endocrinology and Metabolism, Celal Bayar University School of Medicine, Manisa,
Turkey
| | - Hasan Aydın
- Department of Endocrinology and Metabolism, Yeditepe University School of Medicine, İstanbul,
Turkey
| | - Melin Uygur
- Department of Endocrinology and Metabolism, Yeni Yuzyıl University School of Medicine, İstanbul,
Turkey
| | - Ferhat Deniz
- Department of Endocrinology and Metabolism, Health Sciences University School of Medicine, Abdulhamid Han Hospital, İstanbul,
Turkey
| | - Süleyman İpekçi
- Department of Endocrinology and Metabolism, Selçuk University School of Medicine, Konya,
Turkey
| | - Ayşegül Atmaca
- Department of Endocrinology and Metabolism, Ondokuz Mayıs University School of Medicine, Samsun,
Turkey
| | - Fulden Saraç
- Department of Geriatrics, İzmir Ege University School of Medicine, İzmir,
Turkey
| | - Nilüfer Özdemir
- Department of Endocrinology and Metabolism, Celal Bayar University School of Medicine, Manisa,
Turkey
| | - Zeynep Cantürk
- Department of Endocrinology and Metabolism, Kocaeli University School of Medicine, Kocaeli,
Turkey
| | - Meral Mert
- Department of Endocrinology and Metabolism, Health Sciences University School of Medicine, Sadi Konuk Hospital, İstanbul,
Turkey
| | - Seda Sancak
- Department of Endocrinology and Metabolism, Health Sciences University School of Medicine, Fatih Sultan Mehmet Hospital, İstanbul,
Turkey
| | - Eda Ertörer
- Department of Endocrinology and Metabolism, Başkent University School of Medicine, Adana Hospital, Adana,
Turkey
| | - Cevdet Duran
- Department of Endocrinology and Metabolism, Uşak University School of Medicine, Uşak,
Turkey
| | - Ersin Akarsu
- Department of Endocrinology and Metabolism, Gaziantep University School of Medicine, Gaziantep,
Turkey
| | - Oğuzhan Deyneli
- Department of Endocrinology and Metabolism, Koç University School of Medicine, İstanbul,
Turkey
| | - Alev Selek
- Department of Endocrinology and Metabolism, Kocaeli University School of Medicine, Kocaeli,
Turkey
| | - Alper Gürlek
- Hacettepe University Faculty of Medicine Section of Endocrinology and Metabolism, Ankara,
Turkey
| |
Collapse
|
4
|
Can N, Çelik M, Bülbül BY, Süt N, Özyilmaz F, Aytürk S, Güldiken S, Sarikaş N, Puyan FÖ, Yalta TD, Kutlu AK. TERT Expression in Pituitary Adenomas. Turk Patoloji Derg 2017; 33:103-111. [PMID: 28272680 DOI: 10.5146/tjpath.2016.01387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE Although pituitary adenomas have benign histomorphological features, some of them may present in an aggressive manner. To predict the behaviour of these tumours, telomerase reverse transcriptase (TERT) activity in pituitary adenomas has been the subject of a few studies with contradictory results. This study aims to investigate whether immunohistochemical expression of TERT differs in neoplastic and nonneoplastic pituitary tissues and aims to investigate whether TERT expression is related to clinicopathological features of pituitary adenomas. MATERIAL AND METHOD The study included 48 patients who had been diagnosed with pituitary adenomas and had clinical follow-ups. Nonneoplastic pituitary tissues were obtained from autopsy specimens (n=20). Immunohistochemistry for TERT antibody was performed. Both the nuclear and cytoplasmic expression of TERT antibody was noted, and total combined TERT staining was evaluated according to nuclear and cytoplasmic stainings. RESULTS TERT expression did not differ between neoplastic and nonneoplastic pituitary tissues. Neither total (combined nuclear and cytoplasmic) TERT nor nuclear TERT expression revealed any statistically significant relationship with any of the clinicopathological features. Higher cytoplasmic TERT expression was observed in adenomas with recurrence than adenomas without recurrence (p=0.035). CONCLUSION This study introduces the notion that immunohistochemical expression of TERT does not differ in neoplastic and nonneoplastic pituitary tissues. Pituitary adenomas with cytoplasmic immunohistochemical expression of TERT have significantly higher rates of recurrence. Further studies, including combined methods of immunohistochemistry and molecular analyses in larger groups, may reveal applicable results for the clinical significance of TERT in pituitary adenomas.
Collapse
Affiliation(s)
- Nuray Can
- Department of Pathology, Trakya University, Faculty of Medicine, EDİRNE, TURKEY
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Yaylaci S, Demir MV, Aytürk S, Tamer A. Sheehan's syndrome: Presented with hyponatremia and hypoglycemia after 14 years from delivery. Indian J Endocrinol Metab 2012; 16:322-323. [PMID: 22470882 PMCID: PMC3313763 DOI: 10.4103/2230-8210.93783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Selcuk Yaylaci
- Department of Internal Medicine, Sakarya Education and Research Hospital, Sakarya, Turkey
| | - Mustafa Volkan Demir
- Department of Internal Medicine, Sakarya Education and Research Hospital, Sakarya, Turkey
| | - Semra Aytürk
- Department of Internal Medicine, Sakarya Education and Research Hospital, Sakarya, Turkey
| | - Ali Tamer
- Department of Internal Medicine, Sakarya Education and Research Hospital, Sakarya, Turkey
| |
Collapse
|
6
|
Ertugrul DT, Gürsoy A, Yücel M, Sahin M, Unal AD, Pamuk B, Berberoglu Z, Aytürk S, Tutuncu NB, Demirag NG. Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis. Platelets 2009; 17:351-3. [PMID: 16973494 DOI: 10.1080/09537100600746649] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Many studies have addressed the effects of estrogenic compounds on platelet function. Raloxifene is a selective estrogen receptor modulator (SERM), which is currently used for the treatment of postmenopausal osteoporosis. At present, there are no clinical data about the effects of raloxifene on platelet function. The purpose of this study was to determine if raloxifene at therapeutic doses affects platelet function in patients with postmenopausal osteoporosis. The effects of raloxifene on platelet function were investigated using a commercial platelet function analyzer (PFA-100) with collagen epinephrine and collagen adenosine 5'-diphosphate (ADP) cartridges. We studied platelet function of 30 patients with postmenopausal osteoporosis before and 15 days after initiation of raloxifene 60 mg/daily. Closure times did not differ significantly between samples obtained before (117.8 +/- 20.5 s) and after raloxifene therapy (106.5 +/- 25.4 s) in collagen/epinephrine cartridges (P > 0.05). There was also no statistically significant difference in mean closure times with collagen/ADP cartridges at baseline (86.2 +/- 18.5 s) and after raloxifene therapy (84.4 +/- 13.8 s) (P > 0.05). Platelet counts (278.3 +/- 72.9 vs. 262.4 +/- 56.7 109/L, P > 0.05) and mean platelet volumes (8.9 +/- 1 vs. 9.1 +/- 1 fL, P > 0.05) were not different before and after raloxifene therapy. Although estrogen related compounds do affect platelet function, there is suggestive data in our study that raloxifene in therapeutic dose exhibit no effect on platelet function in patients with postmenopausal osteoporosis.
Collapse
Affiliation(s)
- Derun Taner Ertugrul
- Faculty of Medicine, Department of Endocrinology and Metabolism, Baskent University, Ankara, Turkey
| | | | | | | | | | | | | | | | | | | |
Collapse
|